Investigation finds Biogen set 'unjustifiably high price' for Aduhelm; Eric Lander's next act

In the Aduhelm Files, STAT explains the significance of a congressional investigation of the FDA, Biogen, and an Alzheimer's drug approval. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds By Damian Garde and Adam Feuerstein Hyacinth Empinado/STAT Biogen's confidential corporate presentations provide a rare glimpse into the process by which pharmaceutical companies set prices. Read More STAT+: Eric Lander's next act: leading a nonprofit set on solving thorny scientific challenges By Megan Molteni Alex Wong/Getty Images Lander’s next act places a big bet that he can reinvigorate the U.S. science enterprise, this time from outside the halls of government. Read More Watch: The 'fourth wave' of the overdose crisis By Alex Hogan Since the pandemic hit in 2020, a perfect storm of an overwhelmed public health system and a more toxic drug supply made things even more dire. Read More Sponsored Insight by STAT+ Searching for the perfect gift? Get 3 months of STAT+ for $30. A STAT+ subscription gives you unlimited access to in-depth investigative journalism, groundbreaking analysis, subscriber-only newsletters, and industry event discounts. With a premium membership, you’ll get your life sciences news direct from the source. For a limited time only, get three months of STAT+ for just $30. Subscribe now. STAT+: 'Rife with irregularities': Congressional investigation reveals FDA's approval of Aduhelm marked by secret discussions, breaches of protocol By Rachel Cohrs Hyacinth Empinado/STAT House investigators faulted the FDA for glossing over internal disagreements about Aduhelm, and for urging approval for a broad population. Read More FDA, Biogen, and an Alzheimer's drug approval: 8 key takeaways from congressional investigation By Rachel Cohrs and Adam Feuerstein and Damian Garde STAT The congressional report is filled with fresh details about how Biogen plotted with the federal agency that is supposed to regulate it. Read More 3 things to watch in chronic disease in 2023: obesity drugs, long Covid and health care costs By Elaine Chen and Isabella Cueto Christine Kao/STAT We could see the start of a new, tumultuous phase in the long struggle against obesity. And we may start to get answers about long Covid. Read More Opinion: Most-read First Opinion essays of 2022 By Patrick Skerrett Hyacinth Empinado STAT published nearly 500 First Opinion essays in 2022. All are worth reading, or rereading. You can see the 5 most-read essays here. Read More Study could pave way for new antiviral, as China grapples with Covid wave By Jason Mast NOEL CELIS/AFP via Getty Images A trial of a Chinese-developed derivative of remdesevir showed comparable efficacy to Paxlovid in a study published in NEJM. Read More STAT+: Pfizer says hemophilia B gene therapy significantly reduces bleeds By Jason Mast Mark Lennihan/AP Pfizer's trial results come a month after UniQure's treatment was approved as the first gene therapy for hemophilia B. Read More Thursday, December 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser